DGAP-News: WILEX AG: Burrill Securities supports WILEX in exploring financing partners

        Print
| Source: EQS Group AG
DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: Burrill Securities supports WILEX in exploring financing
partners

02.07.2013 / 21:29

---------------------------------------------------------------------

PRESS RELEASE 

Burrill Securities supports WILEX in exploring financing partners 

Munich, Germany / San Francisco, CA, USA, 2 July 2013 - WILEX AG (ISIN
DE0006614720 / WL6 / FSE) has engaged the investment banking firm Burrill
Securities LLC as its exclusive advisor to assist the Company in selecting
partners for the financing of WILEX's projects.

WILEX is a biopharmaceutical company listed on the Frankfurt Stock Exchange
in the Regulated Market / Prime Standard. The Company was founded in 1997
by a team of physicians and oncologists from the Technical University of
Munich. WILEX's mission is to develop diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer. The Company's product candidates are based on antibodies
and small molecules. WILEX Group works within the segments therapeutics,
diagnostics and customer specific research and is one of the most
comprehensive personalized medicine companies in Germany.

Burrill Securities provides life sciences companies with access to
financial resources through global capital and a complementary blend of
financial advisory services on public and private financings and
cross-border transactions, including M&A, strategic partnerships, spinouts,
and public and private capital raising. It provides companies enhanced
access to public market investors through its Institutional Equities
business. Burrill Securities LLC, member FINRA/SIPC is the investment
banking arm of Burrill & Company (www.burrillandco.com).

WILEX's Chief Executive Officer Olaf Wilhelm, MD, PhD commented: 'We
believe that we can best serve the interests of all our shareholders by
exploring every possible alternative to enhance shareholder value as well
as to secure financing of planned future phase III trials'.

'We are excited to work with the WILEX management team to unlock maximum
shareholder value. We have known the Company for a long time and the mix of
targeted therapeutics and diagnostics is a good fit for the market today',
commented Stephen Hurly, CEO Burrill Securities.

About WILEX 
WILEX AG is based in Munich, Germany and focused on oncology. In the field
of therapeutics, WILEX develops antibodies and small molecules.
(RENCAREX(R): Phase III, MESUPRON(R): Phase II, WX-554: Phase Ib/II and
WX-037: preclinical). In the segment diagnostics, REDECTANE(R) is an
antibody-based imaging agent that is currently in a Phase III program. The
Company also has a portfolio of biomarker assays that are marketed via its
US subsidiary WILEX Inc. under the brand Oncogene Science. WILEX's
subsidiary Heidelberg Pharma GmbH offers preclinical contract research
services and a highly promising antibody drug conjugate (ADC) technology
platform. The business model of WILEX comprises research and product
development as well as the commercialization of its activities. WILEX's
customers and partners include leading international pharmaceutical
companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 /
Symbol WL6.

<pre>
Contact:
WILEX AG                                   Burrill Securities
Katja Arnold (CIRO)                        Stephen Hurly
Director Corporate Communications          Managing Director
Grillparzerstr. 10                         1 Embarcadero Center, Suite 2700
81675 Munich, Germany                      San Francisco, CA 94111
Tel.: +49 (0)89-41 31 38-126               USA
Fax: +49 (0)89-41 31 38-99                 Tel: 1-415-591-5457
Email: investors@wilex.com                 Email: shurly@b-c.com
</pre>

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward- looking statements to reflect future
events or developments.


End of Corporate News

---------------------------------------------------------------------

02.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     WILEX AG                                               
             Grillparzerstr. 10                                     
             81675 München                                          
             Germany                                                
Phone:       +49 (0)89 41 31 38 - 0                                 
Fax:         +49 (0)89 41 31 38 - 99                                
E-mail:      info@wilex.com                                         
Internet:    www.wilex.com                                          
ISIN:        DE0006614720                                           
WKN:         661472                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
219569 02.07.2013